
## Graham Ogg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3878479/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17Âyears old. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 17-38.	2.7	19
2	Surveillance of SARS-CoV-2 variants of concern by identification of single nucleotide polymorphisms in the spike protein by a multiplex real-time PCR. Journal of Virological Methods, 2022, 300, 114374.	1.0	5
3	British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021*. British Journal of Dermatology, 2022, 186, 398-413.	1.4	20
4	An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nature Immunology, 2022, 23, 50-61.	7.0	110
5	Phospholipase activity of acyloxyacyl hydrolase induces ILâ€22â€producing CD1aâ€autoreactive T cells in individuals with psoriasis. European Journal of Immunology, 2022, 52, 511-524.	1.6	8
6	Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222. Clinical and Experimental Immunology, 2022, 208, 323-331.	1.1	3
7	Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac). Scientific Reports, 2022, 12, 1727.	1.6	11
8	HLAâ€dependent variation in SARSâ€CoVâ€2 CD8Â <sup>+</sup> T cell crossâ€reactivity with human coronaviruses. Immunology, 2022, 166, 78-103.	2.0	16
9	Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals. Immunity, Inflammation and Disease, 2022, 10, e592.	1.3	6
10	Sensitivity and specificity of two WHO approved SARS-CoV2 antigen assays in detecting patients with SARS-CoV2 infection. BMC Infectious Diseases, 2022, 22, 276.	1.3	13
11	Ni2+-Assisted Hydrolysis May Affect the Human Proteome; Filaggrin Degradation Ex Vivo as an Example of Possible Consequences. Frontiers in Molecular Biosciences, 2022, 9, 828674.	1.6	1
12	Dengue NS1 induces phospholipase A2 enzyme activity, prostaglandins, and inflammatory cytokines in monocytes. Antiviral Research, 2022, 202, 105312.	1.9	6
13	Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell–mediated toxicity against glioblastoma. Neuro-Oncology, 2022, 24, 2093-2106.	0.6	18
14	Persistence of immune responses to the Sinopharm/BBIBP orV vaccine. Immunity, Inflammation and Disease, 2022, 10, .	1.3	20
15	Efficacy of rupatadine in reducing the incidence of dengue haemorrhagic fever in patients with acute dengue: A randomised, double blind, placebo-controlled trial. PLoS Neglected Tropical Diseases, 2022, 16, e0010123.	1.3	4
16	Antibody responses to Sinopharm/BBIBP-CorV in pregnant mothers in Sri Lanka. PLOS Global Public Health, 2022, 2, e0000607.	0.5	1
17	Immune responses to Sinopharm/ <scp>BBIBPâ€CorV</scp> in individuals in Sri Lanka. Immunology, 2022, 167, 275-285.	2.0	8
18	Dengue and COVID-19: two sides of the same coin. Journal of Biomedical Science, 2022, 29, .	2.6	16

#	Article	IF	CITATIONS
19	Comparison of the immunogenicity of five COVIDâ€19 vaccines in Sri Lanka. Immunology, 2022, 167, 263-274.	2.0	12
20	Role of regulatory T cells in psoriasis pathogenesis and treatment. British Journal of Dermatology, 2021, 184, 14-24.	1.4	124
21	Efficacy and safety of dupilumab for moderateâ€ŧoâ€severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 45-58.	2.7	41
22	Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 59-70.	2.7	58
23	Developmental cell programs are co-opted in inflammatory skin disease. Science, 2021, 371, .	6.0	264
24	Human skin is colonized by T cells that recognize CD1a independently of lipid. Journal of Clinical Investigation, 2021, 131, .	3.9	31
25	Urinary leukotrienes and histamine in patients with varying severity of acute dengue. PLoS ONE, 2021, 16, e0245926.	1.1	14
26	CD1a function in human skin disease. Molecular Immunology, 2021, 130, 14-19.	1.0	9
27	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 2021, 12, 2055.	5.8	102
28	Identification of Novel Candidate CD8+ T Cell Epitopes of the SARS-CoV2 with Homology to Other Seasonal Coronaviruses. Viruses, 2021, 13, 972.	1.5	5
29	CD1a selectively captures endogenous cellular lipids that broadly block T cell response. Journal of Experimental Medicine, 2021, 218, .	4.2	24
30	IL-6 effector function of group 2 innate lymphoid cells (ILC2) is NOD2 dependent. Science Immunology, 2021, 6, .	5.6	8
31	Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19. Allergy, Asthma and Clinical Immunology, 2021, 17, 67.	0.9	3
32	Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers. Nature Communications, 2021, 12, 4617.	5.8	44
33	Comparison of two assays to detect IgG antibodies to the receptor binding domain of SARSâ€CoVâ€2 as a surrogate marker for assessing neutralizing antibodies in COVID-19 patients. International Journal of Infectious Diseases, 2021, 109, 85-89.	1.5	18
34	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. PLoS Pathogens, 2021, 17, e1009804.	2.1	39
35	Genomic and Epidemiological Analysis of SARS-CoV-2 Viruses in Sri Lanka. Frontiers in Microbiology, 2021, 12, 722838.	1.5	9
36	SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness. Scientific Reports, 2021, 11, 2062.	1.6	58

#	Article	IF	CITATIONS
37	EAACI Biologicals Guidelines—dupilumab for children and adults with moderateâ€ŧoâ€severe atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 988-1009.	2.7	24
38	The impact of viral mutations on recognition by SARS-CoV-2 specific TÂcells. IScience, 2021, 24, 103353.	1.9	57
39	Immune Responses to a Single Dose of the AZD1222/Covishield Vaccine at 16 Weeks in Individuals in Sri Lanka. Journal of Immunology, 2021, 207, 2681-2687.	0.4	4
40	Transmission dynamics, clinical characteristics and sero-surveillance in the COVID-19 outbreak in a population dense area of Colombo, Sri Lanka April- May 2020. PLoS ONE, 2021, 16, e0257548.	1.1	8
41	Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka. Frontiers in Public Health, 2021, 9, 724398.	1.3	8
42	Atopic dermatitis epidemiology and unmet need in the United Kingdom. Journal of Dermatological Treatment, 2020, 31, 801-809.	1.1	43
43	Advances in the assessment of T-cell clonality. Diagnostic Histopathology, 2020, 26, 388-397.	0.2	0
44	Predicting Cross-Reactivity and Antigen Specificity of T Cell Receptors. Frontiers in Immunology, 2020, 11, 565096.	2.2	45
45	Addressing Differentiation in Live Human Keratinocytes by Assessment of Membrane Packing Order. Frontiers in Cell and Developmental Biology, 2020, 8, 573230.	1.8	9
46	Risk Factors for Elevated Serum Lipopolysaccharide in Acute Dengue and Association with Clinical Disease Severity. Tropical Medicine and Infectious Disease, 2020, 5, 170.	0.9	7
47	Dysfunctional Innate Immune Responses and Severe Dengue. Frontiers in Cellular and Infection Microbiology, 2020, 10, 590004.	1.8	30
48	Similarities and differences between the â€ <sup>~</sup> cytokine storms' in acute dengue and COVID-19. Scientific Reports, 2020, 10, 19839.	1.6	27
49	Re-evaluation of human BDCA-2+ DC during acute sterile skin inflammation. Journal of Experimental Medicine, 2020, 217, .	4.2	29
50	Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nature Immunology, 2020, 21, 1336-1345.	7.0	1,066
51	Potential CD8+ T Cell Cross-Reactivity Against SARS-CoV-2 Conferred by Other Coronavirus Strains. Frontiers in Immunology, 2020, 11, 579480.	2.2	42
52	Identification of Immune Responses to Japanese Encephalitis Virus Specific T Cell Epitopes. Frontiers in Public Health, 2020, 8, 19.	1.3	2
53	Natural killer cells get under your skin. Science Translational Medicine, 2020, 12, .	5.8	2
54	Innate Lymphocyte Mechanisms in Skin Diseases. Annual Review of Immunology, 2020, 38, 171-202.	9.5	10

#	Article	IF	CITATIONS
55	Phenotype and functionality of follicular helper T cells in patients with acute dengue infection. Journal of Biomedical Science, 2020, 27, 50.	2.6	12
56	Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease. JCI Insight, 2020, 5, .	2.3	310
57	Development of an ELISA to Assess Japanese Encephalitis Virus NS1 Protein Antibody Responses in a Community Cohort in Sri Lanka. , 2020, , .		0
58	Altered monocyte response to the dengue virus in those with varying severity of past dengue infection. Antiviral Research, 2019, 169, 104554.	1.9	9
59	Association of dengue virusâ€specific polyfunctional Tâ€cell responses with clinical disease severity in acute dengue infection. Immunity, Inflammation and Disease, 2019, 7, 276-285.	1.3	19
60	Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Science Translational Medicine, 2019, 11, .	5.8	172
61	Capturing the antigen landscape: HLA-E, CD1 and MR1. Current Opinion in Immunology, 2019, 59, 121-129.	2.4	17
62	Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells. Journal of Allergy and Clinical Immunology, 2019, 144, 1722-1726.e10.	1.5	5
63	Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function. Journal of Allergy and Clinical Immunology, 2019, 143, 2329-2333.	1.5	11
64	Spontaneous atopic dermatitis in mice with a defective skin barrier is independent of ILC2 and mediated by ILâ€1β. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1920-1933.	2.7	51
65	A preliminary study on efficacy of rupatadine for the treatment of acute dengue infection. Scientific Reports, 2018, 8, 3857.	1.6	20
66	A randomized controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate vs. ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema Trial (TREAT). British Journal of Dermatology, 2018, 179, 1297-1306.	1.4	14
67	Orchestrated control of filaggrin–actin scaffolds underpins cornification. Cell Death and Disease, 2018, 9, 412.	2.7	42
68	Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 837-850.	2.7	79
69	Regulatory Tâ€cells in acute dengue viral infection. Immunology, 2018, 154, 89-97.	2.0	24
70	Role of NS1 antibodies in the pathogenesis of acute secondary dengue infection. Nature Communications, 2018, 9, 5242.	5.8	67
71	Quantification of dengue virus specific T cell responses and correlation with viral load and clinical disease severity in acute dengue infection. PLoS Neglected Tropical Diseases, 2018, 12, e0006540.	1.3	37
72	Cultured ELISpot Assay to Investigate Dengue Virus Specific T-Cell Responses. Methods in Molecular Biology, 2018, 1808, 165-171.	0.4	17

#	Article	IF	CITATIONS
73	Foxp3+ T reg cells control psoriasiform inflammation by restraining an IFN-l–driven CD8+ T cell response. Journal of Experimental Medicine, 2018, 215, 1987-1998.	4.2	50
74	Activated innate lymphoid cell populations accumulate in human tumour tissues. BMC Cancer, 2018, 18, 341.	1.1	85
75	Killer T cells show their kinder side. Nature, 2018, 555, 594-595.	13.7	4
76	Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma. Mucosal Immunology, 2018, 11, 1408-1419.	2.7	46
77	Cysteinyl leukotriene E 4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D 2 and epithelial cytokines. Journal of Allergy and Clinical Immunology, 2017, 140, 1090-1100.e11.	1.5	130
78	Secretory phospholipase A2 in the pathogenesis of acute dengue infection. Immunity, Inflammation and Disease, 2017, 5, 7-15.	1.3	23
79	Pathogenesis of vascular leak in dengue virus infection. Immunology, 2017, 151, 261-269.	2.0	165
80	IL-17 Receptor A Maintains and Protects the Skin Barrier To Prevent Allergic Skin Inflammation. Journal of Immunology, 2017, 199, 707-717.	0.4	50
81	Deficiency of filaggrin regulates endogenous cysteine protease activity, leading to impaired skin barrier function. Clinical and Experimental Dermatology, 2017, 42, 622-631.	0.6	27
82	Therapeutic vaccines for allergic disease. Npj Vaccines, 2017, 2, 12.	2.9	7
83	CD1a presentation of endogenous antigens by group 2 innate lymphoid cells. Science Immunology, 2017, 2, .	5.6	57
84	Dengue NS1 antigen contributes to disease severity by inducing interleukin (IL)-10 by monocytes. Clinical and Experimental Immunology, 2016, 184, 90-100.	1.1	49
85	Expansion of highly activated invariant natural killer T cells with altered phenotype in acute dengue infection. Clinical and Experimental Immunology, 2016, 185, 228-238.	1.1	6
86	Patterns and causes of liver involvement in acute dengue infection. BMC Infectious Diseases, 2016, 16, 319.	1.3	126
87	Interleukin-33, friend and foe in type-2 immune responses. Current Opinion in Immunology, 2016, 42, 16-24.	2.4	64
88	Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a. Journal of Experimental Medicine, 2016, 213, 2399-2412.	4.2	194
89	Lipid-specific T cells and the skin. British Journal of Dermatology, 2016, 175, 19-25.	1.4	5
90	Lipopolysaccharide acts synergistically with the dengue virus to induce monocyte production of platelet activating factor and other inflammatory mediators. Antiviral Research, 2016, 133, 183-190.	1.9	32

#	Article	IF	CITATIONS
91	Elevated and crossâ€responsive CD1aâ€reactive T cells in bee and wasp venom allergic individuals. European Journal of Immunology, 2016, 46, 242-252.	1.6	51
92	Enhanced isolation of lymphoid cells from human skin. Clinical and Experimental Dermatology, 2016, 41, 552-556.	0.6	12
93	Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study. Journal of the American Academy of Dermatology, 2016, 75, 940-949.	0.6	53
94	Filaggrin inhibits generation of CD1a neolipid antigens by house dust mite–derived phospholipase. Science Translational Medicine, 2016, 8, 325ra18.	5.8	77
95	Group 2 Innate Lymphoid Cells Express Functional NKp30 Receptor Inducing Type 2 Cytokine Production. Journal of Immunology, 2016, 196, 45-54.	0.4	73
96	Spontaneous atopic dermatitis is mediated by innate immunity, with the secondary lung inflammation of the atopic march requiring adaptive immunity. Journal of Allergy and Clinical Immunology, 2016, 137, 482-491.	1.5	117
97	Bee venom processes human skin lipids for presentation by CD1a. Journal of Experimental Medicine, 2015, 212, 149-163.	4.2	98
98	Functionality of Dengue Virus Specific Memory T Cell Responses in Individuals Who Were Hospitalized or Who Had Mild or Subclinical Dengue Infection. PLoS Neglected Tropical Diseases, 2015, 9, e0003673.	1.3	41
99	Platelet Activating Factor Contributes to Vascular Leak in Acute Dengue Infection. PLoS Neglected Tropical Diseases, 2015, 9, e0003459.	1.3	55
100	The Characterization of Varicella Zoster Virus–Specific T Cells in Skin and Blood during Aging. Journal of Investigative Dermatology, 2015, 135, 1752-1762.	0.3	86
101	Prostaglandin D2 and leukotriene E4 synergize to stimulate diverse TH2 functions and TH2 cell/neutrophil crosstalk. Journal of Allergy and Clinical Immunology, 2015, 135, 1358-1366.e11.	1.5	50
102	Change in Dengue and Japanese Encephalitis Seroprevalence Rates in Sri Lanka. PLoS ONE, 2015, 10, e0144799.	1.1	35
103	Polymorphisms of transporter associated with antigen presentation, tumor necrosis factor-α and interleukin-10 and their implications for protection and susceptibility to severe forms of dengue fever in patients in Sri Lanka. Journal of Global Infectious Diseases, 2015, 7, 157.	0.2	17
104	Role of skin homing T cells in acute dengue infection. Annals of Translational Medicine, 2015, 3, 252.	0.7	0
105	Sphingosine 1-Phosphate in Acute Dengue Infection. PLoS ONE, 2014, 9, e113394.	1.1	41
106	Innate lymphoid cells and the skin. BMC Dermatology, 2014, 14, 18.	2.1	23
107	Dengue NS1 antigen as a marker of severe clinical disease. BMC Infectious Diseases, 2014, 14, 570.	1.3	76
108	Histamine enhances keratinocyte-mediated resolution of inflammation by promoting wound healing and response to infection. Clinical and Experimental Dermatology, 2014, 39, 187-195.	0.6	15

#	Article	IF	CITATIONS
109	Combinatorial HLA-peptide bead libraries for high throughput identification of CD8+ T cell specificity. Journal of Immunological Methods, 2014, 403, 72-78.	0.6	8
110	The histamineâ€ <b>s</b> ynthesizing enzyme histidine decarboxylase is upregulated by keratinocytes in atopic skin. British Journal of Dermatology, 2014, 171, 771-778.	1.4	27
111	MHCII-Mediated Dialog between Group 2 Innate Lymphoid Cells and CD4+ T Cells Potentiates Type 2 Immunity and Promotes Parasitic Helminth Expulsion. Immunity, 2014, 41, 283-295.	6.6	601
112	Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. Journal of Allergy and Clinical Immunology, 2014, 133, 1184-1194.e7.	1.5	433
113	Filaggrin-insufficiency in keratinocytes influences responsiveness of allergen-specific T cells to cognate antigen and compounds barrier function deficiency. Clinical Immunology, 2014, 153, 153-155.	1.4	7
114	Cytokine regulation of the epidermal barrier. Clinical and Experimental Allergy, 2013, 43, 586-598.	1.4	41
115	T cell responses in dengue viral infections. Journal of Clinical Virology, 2013, 58, 605-611.	1.6	43
116	A role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis. Journal of Experimental Medicine, 2013, 210, 2939-2950.	4.2	803
117	Serum IL-10 as a marker of severe dengue infection. BMC Infectious Diseases, 2013, 13, 341.	1.3	73
118	Suppression of Virus Specific Immune Responses by IL-10 in Acute Dengue Infection. PLoS Neglected Tropical Diseases, 2013, 7, e2409.	1.3	58
119	Varicella Zoster–Specific CD4+Foxp3+ T Cells Accumulate after Cutaneous Antigen Challenge in Humans. Journal of Immunology, 2013, 190, 977-986.	0.4	50
120	Linking genotype to phenotype on beads: high throughput selection of peptides with biological function. Scientific Reports, 2013, 3, 3030.	1.6	8
121	The Epidermis as an Adjuvant. Journal of Investigative Dermatology, 2012, 132, 940-948.	0.3	56
122	Leukotriene E4 Activates Human Th2 Cells for Exaggerated Proinflammatory Cytokine Production in Response to Prostaglandin D2. Journal of Immunology, 2012, 188, 694-702.	0.4	36
123	Evaluation of the WHO revised criteria for classification of clinical disease severity in acute adult dengue infection. BMC Research Notes, 2012, 5, 645.	0.6	53
124	ILâ€17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Experimental Dermatology, 2012, 21, 104-110.	1.4	188
125	Identification of serotype-specific T cell responses to highly conserved regions of the dengue viruses. Clinical and Experimental Immunology, 2012, 168, 215-223.	1.1	36
126	Cellular and Cytokine Correlates of Severe Dengue Infection. PLoS ONE, 2012, 7, e50387.	1.1	96

#	Article	IF	CITATIONS
127	Pathogenesis of severe dengue infection. Ceylon Medical Journal, 2012, 57, 97.	0.1	22
128	Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain, 2011, 134, 2687-2702.	3.7	78
129	Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes. British Journal of Dermatology, 2011, 165, 492-498.	1.4	143
130	Phenotypic analysis of perennial airborne allergenâ€specific CD4 <sup>+</sup> T cells in atopic and nonâ€atopic individuals. Clinical and Experimental Allergy, 2011, 41, 1555-1567.	1.4	11
131	Common Filaggrin Null Alleles Are Not Associated with Hymenoptera Venom Allergy in Europeans. International Archives of Allergy and Immunology, 2011, 154, 353-355.	0.9	6
132	HLA Class I and Class II Associations in Dengue Viral Infections in a Sri Lankan Population. PLoS ONE, 2011, 6, e20581.	1.1	56
133	Direct Ex-Vivo Evaluation of Pneumococcal Specific T-Cells in Healthy Adults. PLoS ONE, 2011, 6, e25367.	1.1	10
134	Natural killer cells during primary varicella zoster virus infection. Journal of Infection, 2010, 61, 190-192.	1.7	4
135	T cells reactive with the NC16A domain of BP180 are present in vulval lichen sclerosus and lichen planus. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 186-190.	1.3	49
136	Rapid effector function of circulating CD4+ T cells specific for immunodominant regions of the conserved serine/threonine kinase found in Streptococcus pneumoniae (StkP) in healthy adults. FEMS Immunology and Medical Microbiology, 2010, 60, 113-122.	2.7	3
137	Filaggrin null mutations associate with increased frequencies of allergen-specific CD4+ T-helper 2 cells in patients with atopic eczema. British Journal of Dermatology, 2010, 163, 544-549.	1.4	22
138	IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies. British Journal of Cancer, 2010, 102, 727-730.	2.9	26
139	Tracking Antigen-Specific T-Cells during Clinical Tolerance Induction in Humans. PLoS ONE, 2010, 5, e11028.	1.1	45
140	Natural killer cells during primary varicella zoster virus infection. Journal of Infection, 2010, 61, 190-2.	1.7	2
141	ELISPOT and functional T cell analyses using HLA mono-specific target cells. Journal of Immunological Methods, 2009, 350, 150-160.	0.6	2
142	Role of T cells in the pathogenesis of atopic dermatitis. Clinical and Experimental Allergy, 2009, 39, 310-316.	1.4	28
143	Phenotypic analysis of human cd4+ t cells specific for ie63 protein of vzv. Journal of Infection, 2008, 56, 300.	1.7	0
144	Anti-lymphocyte function associated antigen-1 inhibits T-helper 2 function of human allergen-specific CD4+ T cells. British Journal of Dermatology, 2008, 158, 456-462.	1.4	5

#	Article	IF	CITATIONS
145	Identification of an immunodominant region of Fel d 1 and characterization of constituent epitopes. Clinical and Experimental Allergy, 2008, 38, 1760-1768.	1.4	21
146	Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clinical and Experimental Immunology, 2008, 152, 522-531.	1.1	68
147	Viral Load, Clinical Disease Severity and Cellular Immune Responses in Primary Varicella Zoster Virus Infection in Sri Lanka. PLoS ONE, 2008, 3, e3789.	1.1	67
148	Bacterial superantigen facilitates epithelial presentation of allergen to T helper 2 cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5557-5562.	3.3	61
149	Rapid Effector Function of Varicellaâ€Zoster Virus Glycoprotein I–Specific CD4+T Cells Many Decades after Primary Infection. Journal of Infectious Diseases, 2007, 195, 660-664.	1.9	34
150	Immunotherapy with Antibody-Targeted HLA Class I Complexes: Results of in vivo Tumour Cell Killing and Therapeutic Vaccination. Tumor Biology, 2007, 28, 205-211.	0.8	5
151	Human keratinocyte induction of rapid effector function in antigen-specific memory CD4+ and CD8+ T cells. European Journal of Immunology, 2007, 37, 1485-1493.	1.6	102
152	Phenotypic analysis of human CD4 <sup>+</sup> T cells specific for immediate early 63 protein of varicellaâ€zoster virus. European Journal of Immunology, 2007, 37, 3393-3403.	1.6	29
153	Interleukin-4 promotes human CD8+T cell expression of CCR7. Immunology, 2007, 120, 66-72.	2.0	15
154	Persistent central memory phenotype of circulating Fel d 1 peptide/DRB1â^—0101 tetramer-binding CD4+ T cells. Journal of Allergy and Clinical Immunology, 2006, 118, 1350-1356.	1.5	60
155	Defining the T cell antigen proteome of wasp venom. Clinical and Experimental Allergy, 2006, 36, 1274-1280.	1.4	7
156	A novel fluorescent sensitive assay for detection of differential T cell mediated lysis of multiple adherent target cells. Journal of Immunological Methods, 2006, 316, 153-157.	0.6	4
157	Persistent High Frequencies of Varicella-Zoster Virus ORF4 Protein-Specific CD4 + T Cells after Primary Infection. Journal of Virology, 2006, 80, 9772-9778.	1.5	38
158	Role of T cells in the pathogenesis of mucous membrane pemphigoid. Expert Review of Dermatology, 2006, 1, 25-30.	0.3	3
159	Detection of T Lymphocytes Specific for Human Endogenous Retrovirus K (HERV-K) in Patients with Seminoma. AIDS Research and Human Retroviruses, 2006, 22, 52-56.	0.5	53
160	p53-specific CD8+ T-cell responses in individuals with cutaneous squamous cell carcinoma. British Journal of Dermatology, 2005, 153, 987-991.	1.4	15
161	Interleukin-4 induced down-regulation of skin homing receptor expression by human viral-specific CD8+ T cells may contribute to atopic risk of cutaneous infection. Clinical and Experimental Immunology, 2005, 141, 107-115.	1.1	12
162	Longitudinal Analysis of CD8 + T Cells Specific for Structural and Nonstructural Hepatitis B Virus Proteins in Patients with Chronic Hepatitis B: Implications for Immunotherapy. Journal of Virology, 2004, 78, 5707-5719.	1.5	371

#	Article	IF	CITATIONS
163	CD4â^'CD8αα Subset of CD1d-Restricted NKT Cells Controls T Cell Expansion. Journal of Immunology, 2004, 172, 7350-7358.	0.4	54
164	Simplified one-step antibody-HLA directed expansion of HIV-specific cytotoxic T lymphocytes. Aids, 2004, 18, 2099-2101.	1.0	0
165	TLR2 is expressed on activated T cells as a costimulatory receptor. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3029-3034.	3.3	443
166	Rapid effector function of circulating NC16A-specific T cells in individuals with mucous membrane pemphigoid. British Journal of Dermatology, 2004, 151, 1160-1164.	1.4	27
167	Antibody-targeted MHC complex–directed expansion of HIV-1– and KSHV-specific CD8+ lymphocytes: a new approach to therapeutic vaccination. Blood, 2004, 103, 1791-1795.	0.6	18
168	Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood, 2004, 103, 4613-4615.	0.6	62
169	The role of p53 in the immunobiology of cutaneous squamous cell carcinoma. Clinical and Experimental Immunology, 2003, 132, 379-384.	1.1	29
170	Immunopolarization of CD4+ and CD8+ T Cells to Type-1–Like is Associated with Melanocyte Loss in Human Vitiligo. Laboratory Investigation, 2003, 83, 683-695.	1.7	212
171	T-cell immunotherapy of allergic disease: the role of CD8+ T cells. Current Opinion in Allergy and Clinical Immunology, 2003, 3, 475-479.	1.1	3
172	Escaping High Viral Load Exhaustion. Journal of Experimental Medicine, 2002, 195, 1089-1101.	4.2	213
173	Lack of Epstein-Barr virus- and HIV-specific CD27â^ CD8+ T cells is associated with progression to viral disease in HIV-infection. Aids, 2002, 16, 2001-2011.	1.0	57
174	Dynamics of T Cell Responses in HIV Infection. Journal of Immunology, 2002, 168, 3660-3666.	0.4	137
175	Oligomeric MHC molecules and their homologues: state of the art. Journal of Immunological Methods, 2002, 268, 3-7.	0.6	10
176	Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted hla class I/peptide complexes in scid mice. International Journal of Cancer, 2002, 98, 561-566.	2.3	19
177	Comparison between HIV- and CMV-specific T cell responses in long-term HIV infected donors. Clinical and Experimental Immunology, 2002, 130, 509-517.	1.1	53
178	Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nature Medicine, 2002, 8, 379-385.	15.2	1,432
179	Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes. British Journal of Cancer, 2002, 86, 1336-1342.	2.9	23
180	Allergen-specific CD8+ T cells and atopic disease. Journal of Clinical Investigation, 2002, 110, 1283-1291.	3.9	52

#	Article	IF	CITATIONS
181	Allergen-specific CD8+ T cells and atopic disease. Journal of Clinical Investigation, 2002, 110, 1283-1291.	3.9	27
182	Vancomycin-induced linear IgA disease with autoantibodies to BP180 and LAD285 British Journal of Dermatology, 2001, 145, 816-820.	1.4	65
183	High viral burden in the presence of major HIV-specific CD8+ T cell expansions: evidence for impaired CTL effector function. European Journal of Immunology, 2001, 31, 677-686.	1.6	171
184	Direct Measurement of CD4+ and CD8+ T-Cell Responses to CMV in HIV-1-Infected Subjects. Virology, 2001, 279, 459-470.	1.1	92
185	Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy. Hepatology, 2001, 33, 963-971.	3.6	316
186	Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature, 2001, 410, 106-111.	13.7	910
187	Clustered Mutations in HIV-1 Gag Are Consistently Required for Escape from Hla-B27–Restricted Cytotoxic T Lymphocyte Responses. Journal of Experimental Medicine, 2001, 193, 375-386.	4.2	424
188	Cytotoxic T–cell abundance and virus load in human immunodeficiency virus type 1 and human T–cell leukaemia virus type 1. Proceedings of the Royal Society B: Biological Sciences, 2001, 268, 1215-1221.	1.2	54
189	A simple and rapid magnetic bead separation technique for the isolation of tetramer-positive virus-specific CD8 T cells. Aids, 2001, 15, 810-812.	1.0	12
190	Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. Aids, 2000, 14, 225-233.	1.0	140
191	T cell receptor usage of virus-specific CD8 cells and recognition of viral mutations during acute and persistent hepatitis B virus infection. European Journal of Immunology, 2000, 30, 3067-3078.	1.6	45
192	Characterization of HIV-1-Specific Cytotoxic T Lymphocytes Expressing the Mucosal Lymphocyte Integrin CD103 in Rectal and Duodenal Lymphoid Tissue of HIV-1-Infected Subjects. Virology, 2000, 270, 317-327.	1.1	33
193	Incubation Phase of Acute Hepatitis B in Man: Dynamic of Cellular Immune Mechanisms. Hepatology, 2000, 32, 1117-1124.	3.6	359
194	Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes. British Journal of Cancer, 2000, 82, 1058-1062.	2.9	22
195	An Antigenic Threshold for Maintaining Human Immunodeficiency Virus Type 1-specific Cytotoxic T Lymphocytes. Molecular Medicine, 2000, 6, 803-809.	1.9	33
196	Differential Narrow Focusing of Immunodominant Human Immunodeficiency Virus Gag-Specific Cytotoxic T-Lymphocyte Responses in Infected African and Caucasoid Adults and Children. Journal of Virology, 2000, 74, 5679-5690.	1.5	117
197	The Role of Virus-Specific Cd8+ Cells in Liver Damage and Viral Control during Persistent Hepatitis B Virus Infection. Journal of Experimental Medicine, 2000, 191, 1269-1280.	4.2	761
198	Human Immunodeficiency Virus Type 1- and Cytomegalovirus-Specific Cytotoxic T Lymphocytes Can Persist at High Frequency for Prolonged Periods in the Absence of Circulating Peripheral CD4+ T Cells. Journal of Virology, 2000, 74, 1018-1022.	1.5	89

#	Article	IF	CITATIONS
199	HIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function. Journal of Experimental Medicine, 2000, 192, 63-76.	4.2	820
200	Human CD8+ CTL Specific for the Mycobacterial Major Secreted Antigen 85A. Journal of Immunology, 2000, 165, 7088-7095.	0.4	107
201	Functionally Inert HIV-Specific Cytotoxic T Lymphocytes Do Not Play a Major Role in Chronically Infected Adults and Children. Journal of Experimental Medicine, 2000, 192, 1819-1832.	4.2	125
202	Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine, 2000, 19, 764-778.	1.7	329
203	Isolation of Cytomegalovirus-Specific Cytotoxic T-Lymphocytes from Gut-Associated Lymphoid Tissue (GALT) of HIV Type 1-Infected Subjects. AIDS Research and Human Retroviruses, 2000, 16, 1157-1162.	0.5	8
204	Memory CD8 + T cells in HIV infection. Philosophical Transactions of the Royal Society B: Biological Sciences, 2000, 355, 363-367.	1.8	38
205	The dynamics of the cellular immune response to HIV infection: implications for vaccination. Philosophical Transactions of the Royal Society B: Biological Sciences, 2000, 355, 1007-1011.	1.8	24
206	Expansion of HIV-1-specific CD28–CD45RA–CD8+ T cells in chronically HIV-1-infected individuals. Aids, 2000, 14, 2049.	1.0	12
207	DETECTION OF HLA-SPECIFIC IGG ANTIBODIES USING SINGLE RECOMBINANT HLA ALLELES. Transplantation, 2000, 70, 531-536.	0.5	14
208	HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 3848-3853.	3.3	393
209	Quantitation of antigen-specific CD8+ T-cell responses. Immunology Letters, 1999, 66, 77-80.	1.1	27
210	Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors. Immunology Letters, 1999, 66, 9-14.	1.1	101
211	Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology, 1999, 117, 1386-1396.	0.6	331
212	A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. Aids, 1999, 13, 767-777.	1.0	206
213	Isolation of HIV-1-specific cytotoxic T lymphocytes using human leukocyte antigen-coated beads. Aids, 1999, 13, 1991.	1.0	8
214	Strong Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T-Lymphocyte Activity in Sydney Blood Bank Cohort Patients Infected with <i>nef</i> -Defective HIV Type 1. Journal of Virology, 1999, 73, 436-443.	1.5	103
215	Decay Kinetics of Human Immunodeficiency Virus-Specific Effector Cytotoxic T Lymphocytes after Combination Antiretroviral Therapy. Journal of Virology, 1999, 73, 797-800.	1.5	331
216	Longitudinal Phenotypic Analysis of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes: Correlation with Disease Progression. Journal of Virology, 1999, 73, 9153-9160.	1.5	142

#	Article	IF	CITATIONS
217	Distinct Recognition of Non-Clade B Human Immunodeficiency Virus Type 1 Epitopes by Cytotoxic T Lymphocytes Generated from Donors Infected in Africa. Journal of Virology, 1999, 73, 1708-1714.	1.5	67
218	Levels of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T-Lymphocyte Effector and Memory Responses Decline after Suppression of Viremia with Highly Active Antiretroviral Therapy. Journal of Virology, 1999, 73, 6721-6728.	1.5	287
219	Rapid Death of Adoptively Transferred T Cells in Acquired Immunodeficiency Syndrome. Blood, 1999, 93, 1506-1510.	0.6	104
220	Rapid Death of Adoptively Transferred T Cells in Acquired Immunodeficiency Syndrome. Blood, 1999, 93, 1506-1510.	0.6	16
221	HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature, 1998, 391, 795-799.	13.7	1,983
222	Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Current Biology, 1998, 8, 413-416.	1.8	222
223	HLA-peptide tetrameric complexes. Current Opinion in Immunology, 1998, 10, 393-396.	2.4	105
224	Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA. Science, 1998, 279, 2103-2106.	6.0	1,340
225	Direct Visualization of Antigen-specific CD8+T Cells during the Primary Immune Response to Epstein-Barr Virus In Vivo. Journal of Experimental Medicine, 1998, 187, 1395-1402.	4.2	830
226	Oligoclonal Expansions of CD8+ T Cells in Chronic HIV Infection Are Antigen Specific. Journal of Experimental Medicine, 1998, 188, 785-790.	4.2	153
227	Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes. Journal of Experimental Medicine, 1998, 188, 1641-1650.	4.2	475
228	High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo. Journal of Experimental Medicine, 1998, 188, 1203-1208.	4.2	408
229	Four novel cytotoxic T-lymphocyte epitopes in the highly conserved major homology region of HIV-1 Gag, restricted through B*4402, B*1801, A*2601, B*70 (B*1509). Aids, 1998, 12, 1561-1563.	1.0	13
230	Stability of empty and peptide-loaded class II major histocompatibility complex molecules at neutral and endosomal pH: Comparison to class I proteins. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 2495-2500.	3.3	60
231	Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Medicine, 1997, 3, 212-217.	15.2	1,096
232	Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors. Journal of Immunological Methods, 1997, 210, 65-77.	0.6	78
233	Cerebral nocardia abscesses in a patient with AIDS: Correlation of magnetic resonance and white cell scanning images with neuropathological findings. Journal of Infection, 1997, 35, 311-313.	1.7	11
234	Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 15323-15328.	3.3	107

#	Article	IF	CITATIONS
235	Anti-HLA-A2 antibody-enhancement of peptide association with HLA-A2 as detected by cytotoxic T lymphocytes. Nature, 1989, 342, 443-446.	13.7	42
236	Sensitivity and Specificity of Two WHO Approved SARS-CoV-2 Antigen Assays in Detecting Patients with SARS-CoV-2 Infection. SSRN Electronic Journal, 0, , .	0.4	0
237	The Impact of Viral Mutations on Recognition by SARS-CoV-2 Specific T-Cells. SSRN Electronic Journal, 0, , .	0.4	11
238	Longitudinal Profiling of Cytokines and Chemokines in COVID-19 Reveals Inhibitory Mediators IL-1Ra and IL-10 Are Associated with Disease Severity While Elevated RANTES Is an Early Predictor of Mild Disease. SSRN Electronic Journal, 0, , .	0.4	1
239	Exposure of Keratinocytes to Candida Albicans in the Context of Atopic Milieu Induces Changes in the Surface Glycosylation Pattern of Small Extracellular Vesicles to Enhance Their Propensity to Interact With Inhibitory Siglec Receptors. Frontiers in Immunology, 0, 13, .	2.2	7